Whole-Body MRI in Musculoskeletal Oncology: A Comprehensive Review with Recommendations.

Whole-body (WB) MRI has emerged as an attractive method for oncologic evaluation, potentially replacing conventional imaging modalities and providing a one-step wide-coverage assessment of both the skeleton and soft tissues. In addition to providing anatomic information, WB MRI may also yield a functional analysis with the inclusion of diffusion-weighted imaging (DWI). DWI translates microstructural changes, resulting in an excellent alternative to fluorodeoxyglucose PET/CT. WB MRI (with DWI) offers comparable accuracy to PET/CT and has the advantage of avoiding ionizing radiation. Technological advances and the development of faster protocols have prompted greater accessibility of WB MRI, with growing applications in routine practice for the diagnosis, staging, and follow-up of cancer. This review discusses the technical considerations, clinical applications, and accuracy of WB MRI in musculoskeletal oncology. Keywords: Pediatrics, MR Imaging, Skeletal-Axial, Skeletal-Appendicular, Soft Tissues/Skin, Bone Marrow, Extremities, Oncology, Musculoskeletal Imaging © RSNA, 2023.

[1]  E. Prieto,et al.  11C-Methionine PET/CT in Assessment of Multiple Myeloma Patients: Comparison to 18F-FDG PET/CT and Prognostic Value , 2022, International journal of molecular sciences.

[2]  M. Dimopoulos,et al.  Comparison of MRI Features of Fat Fraction and ADC for Early Treatment Response Assessment in Participants with Multiple Myeloma. , 2022, Radiology.

[3]  W. Oyen,et al.  Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma. , 2021, Radiology. Imaging cancer.

[4]  F. Lecouvet,et al.  Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT , 2021, Skeletal Radiology.

[5]  A. B. Hassan,et al.  Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  F. Lecouvet,et al.  3D Whole-Body MRI of the Musculoskeletal System , 2021, Seminars in Musculoskeletal Radiology.

[7]  D. Karow,et al.  Oncologically Relevant Findings Reporting and Data System (ONCO-RADS): Guidelines for the Acquisition, Interpretation, and Reporting of Whole-Body MRI for Cancer Screening. , 2021, Radiology.

[8]  A. Padhani,et al.  Whole‐body magnetic resonance imaging for prostate cancer assessment: Current status and future directions , 2020, Journal of magnetic resonance imaging : JMRI.

[9]  P. Summers,et al.  Whole-body magnetic resonance imaging (WB-MRI) reporting with the METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P): inter-observer agreement between readers of different expertise levels , 2020, Cancer Imaging.

[10]  C. Parker,et al.  Prostate Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  K. Rosendahl,et al.  Whole-body magnetic resonance imaging in children – how and why? A systematic review , 2020, Pediatric Radiology.

[12]  E. Lis,et al.  Whole‐body magnetic resonance imaging as surveillance for subsequent malignancies in preadolescent, adolescent, and young adult survivors of germline retinoblastoma: An update , 2020, Pediatric blood & cancer.

[13]  M. Moseley,et al.  Therapy Response Assessment of Pediatric Tumors with Whole-Body Diffusion-weighted MRI and FDG PET/MRI. , 2020, Radiology.

[14]  M. Galia,et al.  Whole‐body magnetic resonance imaging (WB‐MRI) in lymphoma: State of the art , 2019, Hematological oncology.

[15]  L. Fayad,et al.  Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis , 2019, Skeletal Radiology.

[16]  E. Rizzatti,et al.  Whole-Body Imaging of Multiple Myeloma: Diagnostic Criteria. , 2019, Radiographics : a review publication of the Radiological Society of North America, Inc.

[17]  J. Vilanova,et al.  Update on Whole-body MRI in Musculoskeletal Applications , 2019, Seminars in Musculoskeletal Radiology.

[18]  D. Vriens,et al.  18F-FDG PET-CT versus MRI for detection of skeletal metastasis in Ewing sarcoma , 2019, Skeletal Radiology.

[19]  V. Goh,et al.  Patient preferences for whole-body MRI or conventional staging pathways in lung and colorectal cancer: a discrete choice experiment , 2019, European Radiology.

[20]  H. Schlemmer,et al.  Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). , 2019, Radiology.

[21]  M. Gee,et al.  Current and Emerging Roles of Whole-Body MRI in Evaluation of Pediatric Cancer Patients. , 2019, Radiographics : a review publication of the Radiological Society of North America, Inc.

[22]  Y. Cho,et al.  Comparison of whole-body MRI, bone scan, and radiographic skeletal survey for lesion detection and risk stratification of Langerhans Cell Histiocytosis , 2019, Scientific Reports.

[23]  V. Goh,et al.  Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [18F] fluorodeoxyglucose and [18F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imaging , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  M. Bellomi,et al.  The added value of whole-body magnetic resonance imaging in the management of patients with advanced breast cancer , 2018, PloS one.

[25]  N. Michoux,et al.  Whole Body MRI and oncology: recent major advances. , 2018, The British journal of radiology.

[26]  J. Kraveka,et al.  Updates in Diagnosis, Management, and Treatment of Neuroblastoma. , 2018, Radiographics : a review publication of the Radiological Society of North America, Inc.

[27]  F. Becce,et al.  Bone Marrow Metastases: T2-weighted Dixon Spin-Echo Fat Images Can Replace T1-weighted Spin-Echo Images. , 2017, Radiology.

[28]  M. Picchio,et al.  68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. , 2016, European urology focus.

[29]  Caleb K. Stein,et al.  Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. , 2017, Blood.

[30]  S. Punwani,et al.  Diagnostic utility of whole body Dixon MRI in multiple myeloma: A multi-reader study , 2017, PloS one.

[31]  E. Marchiori,et al.  Whole-body MRI in pediatric patients with cancer , 2017, Cancer Imaging.

[32]  Evis Sala,et al.  METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer☆ , 2017, European urology.

[33]  I. Lewis,et al.  UK Guidelines for the Management of Bone Sarcomas , 2010, Sarcoma.

[34]  F. Lecouvet.  Whole-Body MR Imaging: Musculoskeletal Applications. , 2016, Radiology.

[35]  N. Michoux,et al.  wbMRI to detect bone metastases: critical review on diagnostic accuracy and comparison to other imaging modalities , 2015, Clinical and Translational Imaging.

[36]  Z. Jia,et al.  Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis , 2014, Skeletal Radiology.

[37]  J. Stoker,et al.  Whole-body MRI for initial staging of paediatric lymphoma: prospective comparison to an FDG-PET/CT-based reference standard , 2014, European Radiology.

[38]  L. Fayad,et al.  Whole Body MRI at 3T with Quantitative Diffusion Weighted Imaging and Contrast-Enhanced Sequences for the Characterization of Peripheral Lesions in Patients with Neurofibromatosis Type 2 and Schwannomatosis , 2013, ISRN radiology.

[39]  M. Dimopoulos,et al.  Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: A single center experience on 228 patients , 2012, American journal of hematology.

[40]  M. Askenazi,et al.  Quantitative Assessment of Whole-Body Tumor Burden in Adult Patients with Neurofibromatosis , 2012, PloS one.

[41]  Dominik Weishaupt,et al.  Diagnostic accuracy of whole-body MRI/DWI image fusion for detection of malignant tumours: a comparison with PET/CT , 2011, European Radiology.

[42]  T. Hirai,et al.  The value of diffusion-weighted imaging for monitoring the chemotherapeutic response of osteosarcoma: a comparison between average apparent diffusion coefficient and minimum apparent diffusion coefficient , 2010, Skeletal Radiology.

[43]  P. Choyke,et al.  Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. , 2009, Neoplasia.

[44]  Bernd Hamm,et al.  Diffusion‐weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft‐tissue sarcomas , 2008, Journal of magnetic resonance imaging : JMRI.

[45]  D. Yang,et al.  Whole-body MRI of Langerhans cell histiocytosis: comparison with radiography and bone scintigraphy , 2006, Pediatric Radiology.

[46]  O. Schober,et al.  Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. , 2001, AJR. American journal of roentgenology.